Healthcare Value and Cost-Effectiveness – Efficiency Measurement

Definition and Core Concept

This article defines Healthcare Value as the relationship between health outcomes achieved and the resources (costs) expended to achieve them. Value = Outcomes / Cost. Higher value means better outcomes for the same or lower cost, or similar outcomes at lower cost. Cost-effectiveness analysis (CEA) is a method for comparing value across interventions by measuring incremental costs and health benefits (e.g., quality-adjusted life years – QALYs). Core features: (1) cost measurement (direct medical costs, indirect costs, patient time, caregiver costs), (2) outcome measurement (life-years gained, QALYs, disease-specific outcomes), (3) incremental cost-effectiveness ratio (ICER) calculation, (4) cost-effectiveness thresholds (decision rule for whether an intervention represents good value), (5) budget impact analysis (affordability for a specific payer or system). The article addresses: objectives of value assessment; key concepts including opportunity cost, willingness-to-pay threshold, and dominant interventions; core mechanisms such as decision modelling and sensitivity analysis; international comparisons and debated issues (QALY ethics, threshold variation across countries, value-based pricing); summary and emerging trends (value-based insurance design, alternative payment models, patient-centred value assessment); and a Q&A section.

1. Specific Aims of This Article

This article describes healthcare value and cost-effectiveness without endorsing specific thresholds. Objectives commonly cited: improving efficiency, reducing waste, informing coverage decisions, negotiating drug prices, and allocating limited resources fairly. The article notes that healthcare spending reaches 10-18% of GDP in most high-income countries, and value assessment helps prioritise interventions that provide greatest benefit per dollar.

2. Foundational Conceptual Explanations

Key terminology:

• Quality-adjusted life year (QALY): Composite measure of length and quality of life (0=deaths, 1=perfect health). Enables comparison across different interventions.
• Incremental cost-effectiveness ratio (ICER): (Cost intervention A – Cost intervention B) / (Outcome A – Outcome B). Lower ICER (cost per QALY) indicates better value.
• Dominant intervention: Less costly and more effective than comparator (both ICER numerator negative and denominator positive).
• Cost-effectiveness threshold (willingness to pay): Maximum amount a society (or payer) is willing to pay for one additional QALY. Common ranges: UK (GBP 20,000-30,000), US ($50,000-150,000, no official threshold).
• Budget impact analysis (BIA): Estimates total financial impact of adopting an intervention over 1-5 years, considering eligible population, uptake, and costs offsets.

3. Core Mechanisms and In-Depth Elaboration

Cost categories in CEA:

• Direct medical costs (hospitalisations, procedures, medications, tests, physician visits).
• Direct non-medical costs (transportation, caregiver time, home modifications).
• Indirect costs (productivity loss from illness or premature deaths).

Decision modelling (Markov models, discrete event simulation):

• Synthesise evidence from multiple sources (trials, observational studies, registries).
• Simulate disease progression, treatment pathways, costs, outcomes over lifetime.
• Sensitivity analysis (one-way, probabilistic) to assess parameter uncertainty.

Cost-effectiveness threshold debates:

• No universal threshold exists. Lower thresholds (e.g., GDP per capita – WHO CHOICE) for low-income countries.
• Thresholds derived from opportunity cost (value of health displaced by new expenditure).

Effectiveness evidence (examples):

• Antihypertensive medications: ICER $10,000-30,000 per QALY (very cost-effective).
• Routine mammography for women 40-49: ICER $50,000-100,000 per QALY.
• Ultra-rare disease gene therapies: ICER $500,000-2,000,000 per QALY.

4. International Comparisons and Debated Issues

Value assessment frameworks:

Debated issues:

1. QALY ethics (discrimination against older individuals, disabled persons): QALY assigns lower value to life extension for those with chronic disability (baseline utility <1). Some frameworks (US, IGC) reject QALY for this reason; use equal value of life-years gained (no quality adjustment).
2. High-cost therapies exceeding typical thresholds (gene therapies, cancer immunotherapies): Payers use managed entry agreements, outcomes-based contracts, tiered pricing, and confidential discounts rather than explicit threshold rejection.
3. Budget impact vs cost-effectiveness: An intervention may be cost-effective but unaffordable (large budget impact in short term). Payers consider both.

5. Summary and Future Trajectories

Summary: Healthcare value = outcomes / cost. Cost-effectiveness analysis uses ICER (cost per QALY). Thresholds vary ($50,000-150,000 per QALY typical in US, £20-30k in UK). Budget impact analysis addresses affordability. QALYs remain controversial for disability.

Emerging trends:

• Value-based pricing (drug price linked to clinical benefit): Used for some cancer drug, hepatitis C treatments.
• Alternative payment models (bundled payments, capitation) incentivise value.
• Patient-centred value assessment (including patient preferences, out-of-pocket costs, access).

6. Question-and-Answer Session

Q1: What is the number needed to treat (NNT) and how does it relate to cost-effectiveness?
A: NNT is number of patients needing treatment to prevent one adverse outcome. Cost per event prevented = (NNT × cost per patient). Lower NNT generally improves cost-effectiveness.

Q2: Do all countries use cost-effectiveness analysis for coverage decisions?
A: No. NICE (UK), PBAC (Australia), CADTH (Canada), IQWIG (Germany – efficiency frontier) use CEA. US generally does not use CEA for public coverage decisions (Medicare/Medicaid).

Q3: What is opportunity cost in healthcare?
A: The health benefits foregone when resources are used for one intervention instead of the next best alternative. Opportunity cost is the true cost of any spending. CEA thresholds attempt to reflect this.

Q4: Can cost-effectiveness analysis incorporate equity considerations?
A: Yes. Distributional cost-effectiveness analysis (DCEA) applies weights to outcomes for disadvantaged groups (lower income, rural, minority populations). Not yet standard practice.

https://www.nice.org.uk/
https://icer.org/
https://www.ispor.org/heor-resources/methods-guidelines
https://www.who.int/choice/cost-effectiveness/en/